Human life improved.

NewLimit is an ambitious new company focused on radically extending human healthspan using epigenetic reprogramming therapies.

Our long term ambition is to rejuvenate tissue throughout the whole body. However, we plan on developing intermediary products first, with the first two indications hypothesized to be ocular disease and immunosenescence. An example of the basic research we will be pursuing is mapping age dependent transcriptional and epigenetic shifts using single cell sRNA/ATACseq.

We have $105M in committed funding from the founders for the first 2-3 years of operations, with more capital available upon reasonable progress. We expect to be able to self fund multiple rounds, after which we should have built enough value to raise significant capital from external parties.

Join Us

We're building a new type of biotech, to radically extend human healthspan using cell reprogramming.
Join Us